TABLE 4.
Susceptibilities of C. albicans isolates to fluconazole as determined by NCCLS broth macrodilution testing
| Patient no. | No. of visits | Fluconazole MIC (μg/ml)
|
|
|---|---|---|---|
| 24 h | 48 h | ||
| 1a | 3 | ≤0.125–0.25 | ≤0.125–1 |
| 3a | 3 | 0.25–0.5 | 0.5–2 |
| 6a | 4 | ≤0.125–0.25 | 0.25–2 |
| 7 | 1 | 64b | 64b |
| 11a | 5 | 0.25–0.5 | 0.25–1 |
| 15 | 3 | ≤0.125–0.25 | 0.25 |
| 16 | 7 | 0.25–0.5 | 0.25–2 |
| 17 | 4 | ≤0.125–0.5 | 0.25–1 |
| 18 | 1 | 0.25 | 0.25–0.5 |
| 19 | 1 | 0.25 | 0.25 |
| 20a | 6 | 0.25 | 0.25–0.5 |
| 23 | 5 | ≤0.125–0.5 | 0.25–1 |
| 24a | 7 | ≤0.125–1 | 0.25–2 |
| 25a | 6 | 0.25 | 0.25–1 |
| 26 | 5 | 0.25 | 0.25–0.5 |
a
The patient experienced clinical infection.
b
These were determined to be trailing endpoints, as the organism was susceptible to fluconazole on chromogenic agar.